Trials / Unknown
UnknownNCT03671733
Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Xiangya Hospital of Central South University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This studay evaluates the effect of the glucagon-like peptide-1 (GLP-1) receptor agonist,including Liraglutide,Exenatide and Exenatide Microspheres for Injection,in the treatment of subjects who are overweight or obese.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Liraglutide | The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards, 1.8mg per day, subcutaneous injection. |
| DRUG | Exenatide | 10mcg once a day for 4 weeks increased to 10mcg twice a day for 8 weeks. |
| DRUG | Exenatide Microspheres for Injection | Exenatide 2 mg injection once weekly for 12 weeks. |
Timeline
- Start date
- 2018-09-01
- Primary completion
- 2022-09-01
- Completion
- 2022-09-01
- First posted
- 2018-09-14
- Last updated
- 2021-04-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03671733. Inclusion in this directory is not an endorsement.